Lineage Cell Therapeutics Inc

Research Lineage Cell Therapeutics Inc (LCTX) on Bullrun: market cap USD 336.55M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerLCTX
• ExchangeNYSE MKT
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 336.55M
• Financial periodFY2025
• RevenueUSD 14.56M
• Revenue growth53.2%
• Net income-USD 63.53M
• Free cash flow-USD 19.44M

Valuation Snapshot

latest market cap is USD 336.55M.

About Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration;

Frequently asked questions

What is Lineage Cell Therapeutics Inc's market cap?

Lineage Cell Therapeutics Inc's market capitalization is USD 336.55M.

What does Lineage Cell Therapeutics Inc do?

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.